Journal article
Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation
Abstract
BACKGROUND: Liver transplantation (LT) for hepatitis C virus (HCV)-related end-stage liver disease is impaired by universal disease recurrence and suboptimal response to antiviral therapy. Inhibition of angiotensin-II signalling by angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-II receptor blockers (ARB) decreases hepatic stellate cell activation in vitro and hepatic fibrogenesis in animal models. A single-center retrospective …
Authors
Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
Journal
Transplantation Proceedings, Vol. 45, No. 6, pp. 2331–2336
Publisher
Elsevier
Publication Date
July 2013
DOI
10.1016/j.transproceed.2013.01.067
ISSN
0041-1345